Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

ESMO Asia 2020: Subgroup Analysis of KEYNOTE-522 Supports Use of Pembrolizumab in Triple-Negative Breast Cancer
SITC 2020: Cyclophosphamide Prior to Pembrolizumab in Metastatic Triple-Negative Breast Cancer
ASTRO 2020: Risk of Radiation-Induced Heart Disease in Patients Treated for Breast Cancer
Novel CDK4/6 Inhibitor Plus Fulvestrant Under Study in Advanced Breast Cancer
Pembrolizumab Plus Chemotherapy Receives Accelerated Approval in Triple-Negative Breast Cancer
Early Breast Cancer: Risk-Adapted Targeted Intraoperative Radiotherapy During Lumpectomy
ASTRO 2020: Olaparib Plus Radiotherapy for Advanced Triple-Negative Breast Cancer
Risk of Breast Cancer and Frequency of Pathogenic Variants in Older Women
ASTRO 2020: Initial 2-Year Results of Comparison of Breast Irradiation Therapies
Study Finds Potential Therapeutic Benefit of Honeybee Venom in Breast Cancer Cells
Reduced Dose of Eribulin in Elderly Patients With Advanced Breast Cancer
Global Trends in Premenopausal and Postmenopausal Breast Cancers
North African Breast Cancer Study: Body Image and Sexual Function After Mastectomy
Four-Stranded DNA Structures Identified in Breast Cancer Cells
EBCC 12: Long-Term Survival Outcomes From Phase III Trial in HER2-Positive Breast Cancer
COVID-19 and Breast Cancer Care: Are Younger Patients at Higher Risk of Treatment Delays?
ESMO 2020: Adding Atezolizumab to Chemotherapy Under Study in Triple-Negative Breast Cancer
ESMO 2020: Can Immunotherapy Enhance Effects of Chemotherapy in Triple-Negative Breast Cancer?
ESMO 2020: BRCA Mutations and Treatment Outcomes in Metastatic Breast Cancer
Can Liquid Biopsy Predict Disease Relapse in Triple-Negative Breast Cancer?
ESMO 2020: In-Home Administration of Subcutaneous Trastuzumab Via Single-Use Injection
ESMO 2020: Comparing Neoadjuvant Chemotherapy Regimens in High-Risk Early Breast Cancer
ESMO 2020: Adding Abemaciclib to Hormonal Therapy in High-Risk Early Breast Cancer
IGCS 2020: Does the p53 Protein Have Prognostic Value in Breast Cancer?
Breast Cancer and COVID-19: Treatment Lessons Learned
FDA Issues Alert About Concerns With Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer
Oral Paclitaxel and Encequidar Receives FDA Priority Review in Metastatic Breast Cancer
Dietary Acid Load and Smoking History in Breast Cancer Survivors
Early Breast Cancer Management During the COVID-19 Pandemic: A Case Report
Impact of Surgical Treatment Delay for Patients With Early-Stage Breast Cancer
Exploratory Final Analysis of T-DM1 in Metastatic Breast Cancer: KAMILLA Trial
UK Study Focuses on Survival Outcomes in Breast Cancer During the COVID-19 Pandemic
FDA Amends Guidelines for Male Breast Cancer Clinical Trial Enrollment
Is Pregnancy Safe in Women With Early BRCA-Mutated Breast Cancer?
Potential Link Between Insulin Resistance and Racial Disparities in Breast Cancer Prognosis
Breast Cancer Screening for Childhood Cancer Survivors With a History of Chest Radiotherapy
AACR COVID-19: Using MammaPrint Assay to Guide Chemotherapy Decisions for Breast Cancer
AACR COVID-19: Balancing Risks and Benefits of Surgery for Breast Cancer
FDA Accepts Two Applications for Pembrolizumab in Triple-Negative Breast Cancer
FDA Approves Breast Cancer Companion Diagnostic for Trastuzumab Therapy
AACR COVID-19: Adjustments in Use of CDK4/6 Inhibitors for Metastatic Breast Cancer
Collaborative Palliative Care Intervention for Women With Metastatic Breast Cancer
AACR COVID-19: National Survey of Patient Concerns Regarding Breast Cancer
AACR COVID-19: Recent Trends in Screening for Breast Cancer
BYLieve Trial Supports Use of Alpelisib Plus Fulvestrant for Some Breast Cancers
AACR II: Six New Risk Loci for Breast Cancer Identified in Women of African Ancestry
3-Year TRAIN-2 Update on Neoadjuvant Therapy for HER2-Positive Breast Cancer
AACR II: ARTEMIS Trial of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Can Artificial Intelligence Improve the Accuracy of Screening Mammography Assessment?
Biomarker-Based Update on Neoadjuvant Letrozole With or Without Ribociclib
Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer
AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer
Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer
Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer
AACR II: Study Finds Race-Based Survival Differences in Triple-Negative Breast Cancer
First-in-Human Clinical Trial of Microsurgery Robot to Treat Breast Cancer–Related Lymphedema
ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases
ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?
ASCO20: Which Women With HER2-Positive Early Breast Cancer May Avoid Chemotherapy?
ASCO20: Adding Veliparib to Cisplatin for Select Metastatic Triple-Negative Breast Cancers
ASCO20: MINDACT Update Supports Longer-Term Use of MammaPrint in Clinical Decision-Making
ASCO20: Evaluating Palbociclib Plus Fulvestrant or Letrozole in Metastatic Breast Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.